Cargando…
Efficacy and Safety of Ocriplasmin Use for Vitreomacular Adhesion and Its Predictive Factors: A Systematic Review and Meta-Analysis
Symptomatic vitreomacular adhesion (sVMA) impedes visual acuity and quality. Ocriplasmin is a recombinant protease, which may be injected into the vitreous cavity to treat this condition, yet controversy remains with respect to its effectiveness and safety, particularly its patient selection standar...
Autores principales: | Chen, Xi, Li, Min, You, Ran, Wang, Wei, Wang, Yanling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793778/ https://www.ncbi.nlm.nih.gov/pubmed/35096864 http://dx.doi.org/10.3389/fmed.2021.759311 |
Ejemplares similares
-
Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion
por: Stefanini, Francisco R, et al.
Publicado: (2014) -
Ocriplasmin for symptomatic vitreomacular adhesion: an evidence-based review of its potential
por: Song, Su Jeong, et al.
Publicado: (2014) -
Ocriplasmin for Treatment of Vitreomacular Traction: An Update
por: Khan, Mohammed Ali, et al.
Publicado: (2016) -
Incomplete Vitreomacular Traction Release Using Intravitreal Ocriplasmin
por: Chin, Eric K., et al.
Publicado: (2014) -
OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study
por: Steel, David H. W., et al.
Publicado: (2020)